Article
AKT is a therapeutic target in myeloproliferative neoplasms.
Leukemia - 1 Sept 2013
Khan I, Huang Z, Wen Q, Stankiewicz M J, Gilles L, Goldenson B, Schultz R, Diebold L, Gurbuxani S, Finke C M, Lasho T L, Koppikar P, Pardanani A, Stein B, Altman J K, Levine R L, Tefferi A, Crispino J D
Abstract excerpt
The majority of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) harbor mutations in JAK2 or MPL, which lead to constitutive activation of the JAK/STAT, PI3K and ERK signaling pathways. JAK inhibitors by themselves are inadequate in producing selective clonal suppression in MPN and are associated with hematopoietic toxicities. MK-2206 is a potent allosteric AKT inhibitor that was well tolerated,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.